StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Brady

<< Previous

Bullboard Posts

Next >>

Comment by 4real4everon Aug 19, 2022 12:44pm

132 Views

Post# 34907690

RE:RE:Brady

Like last 6 years

30 Liar Memes That Will Have Every Deceiver's Pants On Fire! - SayingImages.com

LithLover wrote: If you are trying to hint at Tripp not having an incentive or skin in the game you are incorrect.

In addition to his shares there are stock options of nearly 5 million

All issued and outstanding stock options at June 30, 2022 of 4,833,649

And re-read the new from yesterday: all with a view to minimizing dilution for the Company's shareholders," commented James Howard-Tripp, Chairman and CEO of StageZero Life Sciences.

4real4ever wrote:
Insider Roster

Individual or Entity Most Recent Transaction Date Shares Owned as of Transaction Date

*Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.

HEALTH CLINICS LIMITED
10% Security Holder of Issuer

Opening Balance-Initial SEDI Report
Sep 01, 2021
12,400,000

HOWARD-TRIPP (JAMES)
Director of Issuer

Acquisition or disposition in the public market
Aug 18, 2021
261,059

Individual or Entity	Most Recent Transaction	Date	Shares Owned as of Transaction Date
*Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.
HEALTH CLINICS LIMITED 10% Security Holder of Issuer	Opening Balance-Initial SEDI Report	Sep 01, 2021	12,400,000
HOWARD-TRIPP (JAMES) Director of Issuer	Acquisition or disposition in the public market	Aug 18, 2021	261,059